698 related articles for article (PubMed ID: 34210893)
41. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
Cao Y; Yisimayi A; Bai Y; Huang W; Li X; Zhang Z; Yuan T; An R; Wang J; Xiao T; Du S; Ma W; Song L; Li Y; Li X; Song W; Wu J; Liu S; Li X; Zhang Y; Su B; Guo X; Wei Y; Gao C; Zhang N; Zhang Y; Dou Y; Xu X; Shi R; Lu B; Jin R; Ma Y; Qin C; Wang Y; Feng Y; Xiao J; Xie XS
Cell Res; 2021 Jul; 31(7):732-741. PubMed ID: 34021265
[TBL] [Abstract][Full Text] [Related]
42. Analysis of the molecular mechanism of SARS-CoV-2 antibodies.
Jin D; Wei J; Sun J
Biochem Biophys Res Commun; 2021 Aug; 566():45-52. PubMed ID: 34116356
[TBL] [Abstract][Full Text] [Related]
43. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
Chen RE; Zhang X; Case JB; Winkler ES; Liu Y; VanBlargan LA; Liu J; Errico JM; Xie X; Suryadevara N; Gilchuk P; Zost SJ; Tahan S; Droit L; Turner JS; Kim W; Schmitz AJ; Thapa M; Wang D; Boon ACM; Presti RM; O'Halloran JA; Kim AHJ; Deepak P; Pinto D; Fremont DH; Crowe JE; Corti D; Virgin HW; Ellebedy AH; Shi PY; Diamond MS
Nat Med; 2021 Apr; 27(4):717-726. PubMed ID: 33664494
[TBL] [Abstract][Full Text] [Related]
44. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.
Greaney AJ; Starr TN; Barnes CO; Weisblum Y; Schmidt F; Caskey M; Gaebler C; Cho A; Agudelo M; Finkin S; Wang Z; Poston D; Muecksch F; Hatziioannou T; Bieniasz PD; Robbiani DF; Nussenzweig MC; Bjorkman PJ; Bloom JD
Nat Commun; 2021 Jul; 12(1):4196. PubMed ID: 34234131
[TBL] [Abstract][Full Text] [Related]
45. Antibody evasion by the P.1 strain of SARS-CoV-2.
Dejnirattisai W; Zhou D; Supasa P; Liu C; Mentzer AJ; Ginn HM; Zhao Y; Duyvesteyn HME; Tuekprakhon A; Nutalai R; Wang B; López-Camacho C; Slon-Campos J; Walter TS; Skelly D; Costa Clemens SA; Naveca FG; Nascimento V; Nascimento F; Fernandes da Costa C; Resende PC; Pauvolid-Correa A; Siqueira MM; Dold C; Levin R; Dong T; Pollard AJ; Knight JC; Crook D; Lambe T; Clutterbuck E; Bibi S; Flaxman A; Bittaye M; Belij-Rammerstorfer S; Gilbert SC; Carroll MW; Klenerman P; Barnes E; Dunachie SJ; Paterson NG; Williams MA; Hall DR; Hulswit RJG; Bowden TA; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR
Cell; 2021 May; 184(11):2939-2954.e9. PubMed ID: 33852911
[TBL] [Abstract][Full Text] [Related]
46. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Liu C; Ginn HM; Dejnirattisai W; Supasa P; Wang B; Tuekprakhon A; Nutalai R; Zhou D; Mentzer AJ; Zhao Y; Duyvesteyn HME; López-Camacho C; Slon-Campos J; Walter TS; Skelly D; Johnson SA; Ritter TG; Mason C; Costa Clemens SA; Gomes Naveca F; Nascimento V; Nascimento F; Fernandes da Costa C; Resende PC; Pauvolid-Correa A; Siqueira MM; Dold C; Temperton N; Dong T; Pollard AJ; Knight JC; Crook D; Lambe T; Clutterbuck E; Bibi S; Flaxman A; Bittaye M; Belij-Rammerstorfer S; Gilbert SC; Malik T; Carroll MW; Klenerman P; Barnes E; Dunachie SJ; Baillie V; Serafin N; Ditse Z; Da Silva K; Paterson NG; Williams MA; Hall DR; Madhi S; Nunes MC; Goulder P; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR
Cell; 2021 Aug; 184(16):4220-4236.e13. PubMed ID: 34242578
[TBL] [Abstract][Full Text] [Related]
47. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.
Wang L; Zhou T; Zhang Y; Yang ES; Schramm CA; Shi W; Pegu A; Oloniniyi OK; Henry AR; Darko S; Narpala SR; Hatcher C; Martinez DR; Tsybovsky Y; Phung E; Abiona OM; Antia A; Cale EM; Chang LA; Choe M; Corbett KS; Davis RL; DiPiazza AT; Gordon IJ; Hait SH; Hermanus T; Kgagudi P; Laboune F; Leung K; Liu T; Mason RD; Nazzari AF; Novik L; O'Connell S; O'Dell S; Olia AS; Schmidt SD; Stephens T; Stringham CD; Talana CA; Teng IT; Wagner DA; Widge AT; Zhang B; Roederer M; Ledgerwood JE; Ruckwardt TJ; Gaudinski MR; Moore PL; Doria-Rose NA; Baric RS; Graham BS; McDermott AB; Douek DC; Kwong PD; Mascola JR; Sullivan NJ; Misasi J
Science; 2021 Aug; 373(6556):. PubMed ID: 34210892
[TBL] [Abstract][Full Text] [Related]
48. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
Shen X; Tang H; Pajon R; Smith G; Glenn GM; Shi W; Korber B; Montefiori DC
N Engl J Med; 2021 Jun; 384(24):2352-2354. PubMed ID: 33826819
[No Abstract] [Full Text] [Related]
49. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Saxton M; Piantadosi A; Waggoner JJ; Douek DC; Rouphael N; Wrammert J; Suthar MS
Cell Rep Med; 2022 Feb; 3(2):100529. PubMed ID: 35233550
[TBL] [Abstract][Full Text] [Related]
50. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
Schmidt F; Weisblum Y; Rutkowska M; Poston D; DaSilva J; Zhang F; Bednarski E; Cho A; Schaefer-Babajew DJ; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Nature; 2021 Dec; 600(7889):512-516. PubMed ID: 34544114
[TBL] [Abstract][Full Text] [Related]
51. Emerging mutation patterns in SARS-CoV-2 variants.
Ostrov DA; Knox GW
Biochem Biophys Res Commun; 2022 Jan; 586():87-92. PubMed ID: 34837837
[TBL] [Abstract][Full Text] [Related]
52. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
McCallum M; De Marco A; Lempp FA; Tortorici MA; Pinto D; Walls AC; Beltramello M; Chen A; Liu Z; Zatta F; Zepeda S; di Iulio J; Bowen JE; Montiel-Ruiz M; Zhou J; Rosen LE; Bianchi S; Guarino B; Fregni CS; Abdelnabi R; Foo SC; Rothlauf PW; Bloyet LM; Benigni F; Cameroni E; Neyts J; Riva A; Snell G; Telenti A; Whelan SPJ; Virgin HW; Corti D; Pizzuto MS; Veesler D
Cell; 2021 Apr; 184(9):2332-2347.e16. PubMed ID: 33761326
[TBL] [Abstract][Full Text] [Related]
53. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.
Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960755
[TBL] [Abstract][Full Text] [Related]
54. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
55. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
[TBL] [Abstract][Full Text] [Related]
56. The effect of spike mutations on SARS-CoV-2 neutralization.
Rees-Spear C; Muir L; Griffith SA; Heaney J; Aldon Y; Snitselaar JL; Thomas P; Graham C; Seow J; Lee N; Rosa A; Roustan C; Houlihan CF; Sanders RW; Gupta RK; Cherepanov P; Stauss HJ; Nastouli E; ; Doores KJ; van Gils MJ; McCoy LE
Cell Rep; 2021 Mar; 34(12):108890. PubMed ID: 33713594
[TBL] [Abstract][Full Text] [Related]
57. Evolving threat.
Kupferschmidt K
Science; 2021 Aug; 373(6557):844-849. PubMed ID: 34413220
[No Abstract] [Full Text] [Related]
58. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants.
Reynolds CJ; Gibbons JM; Pade C; Lin KM; Sandoval DM; Pieper F; Butler DK; Liu S; Otter AD; Joy G; Menacho K; Fontana M; Smit A; Kele B; Cutino-Moguel T; Maini MK; Noursadeghi M; ; Brooks T; Semper A; Manisty C; Treibel TA; Moon JC; ; McKnight Á; Altmann DM; Boyton RJ
Science; 2022 Jan; 375(6577):183-192. PubMed ID: 34855510
[TBL] [Abstract][Full Text] [Related]
59. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
Muik A; Wallisch AK; Sänger B; Swanson KA; Mühl J; Chen W; Cai H; Maurus D; Sarkar R; Türeci Ö; Dormitzer PR; Şahin U
Science; 2021 Mar; 371(6534):1152-1153. PubMed ID: 33514629
[TBL] [Abstract][Full Text] [Related]
60. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
